Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

2seventy bio, Inc. - Common Stock (NQ: TSVT )

4.630 -0.180 (-3.74%)
Streaming Delayed Price Updated: 3:29 PM EDT, Oct 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 2seventy bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
2seventy bio to Participate in Upcoming Healthcare Conferences
From 2seventy bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Oncternal Therapeutics (NASDAQ:ONCT 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares rose 19.8% to $8.18 during Thursday's pre-market session. The market value of their outstanding shares is at $71.4 million. VYNE... 
Via Benzinga
Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum
2seventy bio Inc's (NASDAQ: TSVT) anti-BCMA CAR-T got axed as part of a corporate update. The treatment was under development in collaboration with Bristol... 
Via Benzinga
2seventy bio Shares Key Milestones and Business Updates for 2022
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach
From 2seventy bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
Upgrades For Canada Goose Holdings Inc (NYSE: 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Before 10 am on Wednesday, 99 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: Sea (NYSE:SE) was the largest firm by market cap to set a... 
Via Benzinga
3 Best Performing Healthcare IPOs in 2021
Healthcare IPOs, 2seventy bio, Inc., Regencell Bioscience Holdings Limited, and Biofrontera Inc. have generated significant returns since their stock market debut and could be ideal additions to one’s... 
Via Talk Markets
2seventy bio Presents Data Across Multiple Cell Therapy Programs at ASH 2021 Annual Meeting
From 2seventy bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Celyad Oncology (NASDAQ:CYAD) shares rose 22.75% to $4.37 during Friday's pre-market session. The company's market cap stands at $70.3 million. Biolase (... 
Via Benzinga
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
41 Stocks Moving In Monday's Mid-Day Session
Gainers Casper Sleep Inc. (NYSE: CSPR) shares climbed 87.1% to $6.64 after the company agreed to be acquired by Durational Capital Management. The company also reported Q3... 
Via Benzinga
2seventy bio to Present at the 5th Annual Cowen IO Next Summit
From 2seventy bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
Upgrades For Nektar Therapeutics (NASDAQ: 
Via Benzinga
64 Biggest Movers From Yesterday
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced the launch of its E-Boost portfolio of mobile... 
Via Benzinga
2seventy bio to Present Data from its Portfolio of Oncology Cell Therapies at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
From 2seventy bio, Inc.
Via Business Wire
92 Biggest Movers From Friday
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the... 
Via Benzinga
64 Stocks Moving In Friday's Mid-Day Session
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the... 
Via Benzinga
2seventy bio Completes Spin Transaction and Launches Innovative Immuno-oncology Cell Therapy Company
From 2seventy bio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.